Rabbit anti-Human TET2 Polyclonal Antibody | anti-TET2 antibody

TET2 Antibody

Cat. Num. AAA151534

• Gene Names: TET2; MDS; KIAA1546
• Reactivity: Human
• Applications: ELISA, Western Blot
• Purity: TET2 Antibody is affinity chromatography purified via peptide column.
• Synonyms: TET2; Polyclonal Antibody; TET2 Antibody; MDS; KIAA1546; Nbla00191; Methylcytosine dioxygenase TET2; tet methylcytosine dioxygenase 2; anti-TET2 antibody

• Host: Rabbit
• Reactivity: Human
• Clonality: Polyclonal
• Isotype: IgG
• Specificity: At least two isoforms of TET2 are known to exist; this antibody will detect both isoforms.
• Purity/Purification: TET2 Antibody is affinity chromatography purified via peptide column.
• Form/Format: Liquid
• Concentration: 1 mg/mL (varies by lot)
• Sequence Length: 2002

• Applicable Applications for anti-TET2 antibody: ELISA (EIA), Western Blot (WB)
• Application Notes: TET2 antibody can be used for detection of TET2 by Western blot at 1 mug/mL.
• Conjugate: Unconjugated
• Immunogen: TET2 antibody was raised against an 18 amino acid synthetic peptide near the amino terminus of human TET2.
• Buffer: TET2 Antibody is supplied in PBS containing 0.02% sodium azide.
• Preparation and Storage: TET2 antibody can be stored at 4 degree C for three months and -20 degree C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

Western Blot (WB)

(Western blot analysis of TET2 in SK-N-SH cell lysate with TET2 antibody at 1 μg/mL.)

Immunohistochemistry (IHC)

(Immunohistochemistry of TET2 in human colon carcinoma tissue with TET2 antibody at 2 μg/ml.)

Immunofluorescence (IF)

(Immunofluorescence of TET2 in human colon carcinoma tissue with TET2 antibody at 20 μg/ml.Green: TET2 Antibody (6915)Blue: DAPI staining)

Related Product Information for anti-TET2 antibody

TET2 Antibody: TET2, a member of the ten-eleven-translocation (TET) family of genes, is a methylcytosine dioxygenase that catalyzes the conversion of methylcytosine to 5-hydroxymethylcytosine. It is a candidate tumor suppressor gene reported to be mutated in approximately 14% of patients with JAK2V617F-positive myeloproliferative neoplasms, and can be mutated in other hematopoietic disorders such as myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia. Analysis of the TET2 and JAK2 mutations in these neoplasms suggests that mutations in TET2 do not represent a predisposition for acquiring mutations in JAK2.

NCBI and Uniprot Product Information

• NCBI GI #: 187761317
• NCBI GeneID: 54790
• NCBI Accession #: NP_001120680
• NCBI GenBank Nucleotide #: NM_001127208.2
• UniProt Accession #: Q6N021; Q2TB88; Q3LIB8; Q96JX5; Q9HCM6; Q9NXW0; B5MDU0
• Molecular Weight: 133,481 Da
• NCBI Official Full Name: methylcytosine dioxygenase TET2 isoform a
• NCBI Official Synonym Full Names: tet methylcytosine dioxygenase 2
• NCBI Official Symbol: TET2
• NCBI Official Synonym Symbols: MDS; KIAA1546
• NCBI Protein Information: methylcytosine dioxygenase TET2; tet oncogene family member 2; probable methylcytosine dioxygenase TET2
• UniProt Protein Name: Methylcytosine dioxygenase TET2
• Protein Family: Tetraspanin
• UniProt Gene Name: TET2
• UniProt Synonym Gene Names: KIAA1546
• UniProt Entry Name: TET2_HUMAN

NCBI Description

The protein encoded by this gene is a methylcytosine dioxygenase that catalyzes the conversion of methylcytosine to 5-hydroxymethylcytosine. The encoded protein is involved in myelopoiesis, and defects in this gene have been associated with several myeloproliferative disorders. Two variants encoding different isoforms have been found for this gene. [provided by RefSeq, Mar 2011]

Uniprot Description

TET2: Catalyzes the conversion of methylcytosine (5mC) to 5- hydroxymethylcytosine (hmC). Plays an important role in myelopoiesis. The clear function of 5-hydroxymethylcytosine (hmC) is still unclear but it may influence chromatin structure and recruit specific factors or may constitute an intermediate component in cytosine demethylation. TET2 is frequently mutated in myeloproliferative disorders (MPD). These constitute a heterogeneous group of disorders, also known as myeloproliferative diseases or myeloproliferative neoplasms (MPN), characterized by cellular proliferation of one or more hematologic cell lines in the peripheral blood, distinct from acute leukemia. Included diseases are: essential thrombocythemia, polycythemia vera, primary myelofibrosis (chronic idiopathic myelofibrosis). Bone marrow samples from patients display uniformly low levels of hmC in genomic DNA compared to bone marrow samples from healthy controls as well as hypomethylation relative to controls at the majority of differentially methylated CpG sites. Defects in TET2 are a cause of polycythemia vera (PV). A myeloproliferative disorder characterized by abnormal proliferation of all hematopoietic bone marrow elements, erythroid hyperplasia, an absolute increase in total blood volume, but also by myeloid leukocytosis, thrombocytosis and splenomegaly. TET2 is frequently mutated in systemic mastocytosis; also known as systemic mast cell disease. A condition with features in common with myeloproliferative diseases. It is a clonal disorder of the mast cell and its precursor cells. The clinical symptoms and signs of systemic mastocytosis are due to accumulation of clonally derived mast cells in different tissues, including bone marrow, skin, the gastrointestinal tract, the liver, and the spleen. Defects in TET2 are a cause of myelodysplastic syndrome (MDS). A heterogeneous group of closely related clonal hematopoietic disorders. All are characterized by a hypercellular or hypocellular bone marrow with impaired morphology and maturation, dysplasia of the myeloid, megakaryocytic and/or erythroid lineages, and peripheral blood cytopenias resulting from ineffective blood cell production. Included diseases are: refractory anemia (RA), refractory anemia with ringed sideroblasts (RARS), refractory anemia with excess blasts (RAEB), refractory cytopenia with multilineage dysplasia and ringed sideroblasts (RCMD-RS). Chronic myelomonocytic leukemia (CMML) is a myelodysplastic/myeloproliferative disease. Myelodysplastic syndromes are considered a premalignant condition in a subgroup of patients that often progresses to acute myeloid leukemia (AML). Bone marrow samples from patients display uniformly low levels of hmC in genomic DNA compared to bone marrow samples from healthy controls as well as hypomethylation relative to controls at the majority of differentially methylated CpG sites. Belongs to the TET family. 3 isoforms of the human protein are produced by alternative splicing.

Protein type: EC 1.14.11.n2; Oxidoreductase; Tumor suppressor

Chromosomal Location of Human Ortholog: 4q24

Molecular Function: protein binding; DNA binding; zinc ion binding; ferrous iron binding

Biological Process: spleen development; protein amino acid O-linked glycosylation; hemoglobin metabolic process; cell cycle; regulation of gene expression, epigenetic; post-embryonic development; cytosine metabolic process; myeloid progenitor cell differentiation; 5-methylcytosine catabolic process; gene expression; positive regulation of transcription from RNA polymerase II promoter; myeloid cell differentiation; kidney development

Disease: Myelodysplastic Syndrome